PVP Procedure Based on Laser System

A new procedure for the treatment of benign prostatic hyperplasia (BPH) is based on a laser system. The procedure has been approved for treating BPH in National Health Service (NHS) hospitals in England and Wales by the U.K. National Institute for Health and Clinical Excellence (NICE, London).

The procedure, called the photoselective vaporization of the prostate (PVP), was developed by Laserscope (San Jose, CA, USA). NICE approved the procedure after recent clinical studies showed excellent treatment results using the company's GreenLight PV laser system. In its review, NICE noted that the PVP procedure is satisfactorily safe, efficient, and effective for the treatment of BPH within the NHS system.

"Late last year, King's College in London was granted a prestigious award by the NHS for demonstrating the success of the PVP procedure on an outpatient basis, versus the more invasive trans-urethral resection of the prostate, or TURP, procedure,” noted Eric Reuter, president and CEO of LaserScope. "The award cited the hospital's ability to reduce costs and waiting times, while increasing patient satisfaction and experience through utilization of the PVP procedure.”

NICE is an independent organization formed in April 1999 to create a single excellence-in-practice body responsible for providing national guidance in the United Kingdom on the promotion of good health and the prevention and treatment of illness. NICE provides guidance to the NHS.

"Our number one priority has been to ensure that PVP using Laserscope's GreenLight PV laser system technology is recognized as the worldwide standard of care for treating BPH, and we believe we are getting closer and closer to achieving that goal every day,” added Mr. Reuter.




Related Links:
Laserscope >>